Therefore, the melanoma network in which a variety of treatment options areconsidered including newer immuno-oncologic therapies, such as BRAF, MEK and PD-1inhibitors, as well as traditional chemotherapy regimens reflects a commonlyencountered situation in which there are many treatment options available but alimited amount of direct head-to-head evidence. This evidence concerns the gene BRAF and melanoma.